ライフサイエンスコーパス: anticoagulation

1 e and cardiovascular comorbidities requiring anticoagulation.

2 whose symptoms fail to resolve with adequate anticoagulation.

3 nd inexpensive form of heparin-free regional anticoagulation.

4 ffering a major intracranial hemorrhage with anticoagulation.

5 with decreased concentrations for markers of anticoagulation.

6 d poor prognosis after a major hemorrhage on anticoagulation.

7 art valves who received different methods of anticoagulation.

8 Both treatment arms received standard anticoagulation.

9 sed plasma creatinine, and planned long-term anticoagulation.

10 erebral bleeding, especially with the use of anticoagulation.

11 Intention to administer therapeutic anticoagulation.

12 least 24 h, and/or requiring interruption of anticoagulation.

13 when it comes to deciding on the duration of anticoagulation.

14 ing adverse event in patients receiving oral anticoagulation.

15 ecurrent venous thromboembolism (VTE) during anticoagulation.

16 are generally managed with rate control and anticoagulation.

17 w we think about perioperative management of anticoagulation.

18 have additional indications for therapeutic anticoagulation.

19 anial hemorrhage for LAA closure and medical anticoagulation.

20 e outcomes of pregnancy in women who require anticoagulation.

21 at baseline than those treated with standard anticoagulation.

22 (5%) patients had a gap of >/=5 mm requiring anticoagulation.

23 rial fibrillation and an indication for oral anticoagulation.

24 recurrent VTE in women receiving therapeutic anticoagulation.

25 ern about the risk/benefit ratio for chronic anticoagulation.

26 blation while obviating the need for chronic anticoagulation.

27 igatran in addition to aspirin for long-term anticoagulation.

28 is limited data on the safety of therapeutic anticoagulation.

29 scular risk factor management in addition to anticoagulation.

30 may identify subgroups that may benefit from anticoagulation.

31 nt preference and values regarding long-term anticoagulation.

32 n equipoise regarding the need for continued anticoagulation.

33 eding complications in patients treated with anticoagulation.

34 often among patients who received parenteral anticoagulation (1163 of 13505 [8.6%]) than patients who

35 ients (83.6%) were not receiving therapeutic anticoagulation; 12751 (13.5%) had subtherapeutic warfar

36 elop a major ICH than those not treated with anticoagulation (14.7% vs 2.5%; P = .036; hazard ratio [

37 xaparin compared with patients not receiving anticoagulation (3.3 vs 10.2 months; log-rank P = .012).

38 ians in the decision of whether to interrupt anticoagulation; 3) provide direction on how to interrup

39 than patients who did not receive parenteral anticoagulation (979 of 13505 [7.2%]; RR, 1.21; 95% CI,

40 For women who require long-term anticoagulation, a levonorgestrel intrauterine system, t

41 Interruption of oral anticoagulation (AC) for surgery or an invasive procedur

42 he presence/absence of a contraindication to anticoagulation (active bleeding, major surgery).

43 e well understood, the management of further anticoagulation after a breakthrough event is based on m

44 The optimal duration of anticoagulation after a first episode of unprovoked pulm

45 omplications following bypass surgery, under anticoagulation after a recent aortic valve replacement

46 important when planning to start or restart anticoagulation after an intracerebral hemorrhage.

47 Cardiology guidelines recommend 3 months of anticoagulation after replacement of the aortic valve wi

48 ximal deep-vein thrombosis to receive either anticoagulation alone (control group) or anticoagulation

49 ectomy is reasonable, while for low-risk PE, anticoagulation alone is often chosen.

50 s anticoagulation (filter group; n = 200) or anticoagulation alone with no filter implantation (contr

51 rates were 14.4% during approved alternative anticoagulation and 0.0% during fondaparinux treatment.

52 In addition to anticoagulation and an adenosine diphosphate-antagonist

53 After a year of anticoagulation and compression therapy, although exacer

54 ntribution of acid-citrate-dextrose regional anticoagulation and dextrose-containing replacement flui

55 f patients treated with approved alternative anticoagulation and in 0.0% of fondaparinux-treated pati

56 thrombotic sequelae, while avoiding systemic anticoagulation and its associated risks.

57 thrombotic sequelae, while avoiding systemic anticoagulation and its associated risks.

58 In contrast to INR, it is independent of anticoagulation and other analytical limitations of coag

59 performance with the CHA2DS2VASc and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation)

60 We assessed this association in the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation)

61 Women had similar rates of anticoagulation and similar time in therapeutic range.

62 Patients already receiving therapeutic anticoagulation and those with a chronic calf DVT, a con

63 transfusion strategies, use of prophylactic anticoagulation and treatment of thromboembolic events i

64 with bacteremia, persistent symptoms despite anticoagulation, and if the CVAD is no longer needed.

65 apy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization g

66 Patients were divided into 3 groups: anticoagulation, antiplatelet, and no therapy cohorts.

67 patients who may benefit from more intensive anticoagulation approaches.

68 Interventions beyond anticoagulation are needed to further reduce mortality i

69 of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.

70 nduced thrombocytopenia requires alternative anticoagulation at a therapeutic dose and immune thrombo

71 and chronic kidney disease), and the use of anticoagulation at discharge (odds ratio, 1.16; 95% conf

72 hromboembolism who had a contraindication to anticoagulation because of active bleeding.

73 et needs and reduce the systemic underuse of anticoagulation because of the fear of bleeding.

74 .4); odds ratio of change in the use of oral anticoagulation between groups was 3.28 (95% CI 1.67-6.4

75 Anticoagulation (both NOACs and warfarin), but not dual

76 no-venous hemodialysis with regional citrate anticoagulation by initial lactate concentrations and la

77 hromboembolism prevention, and management of anticoagulation can be challenging.

78 r biomarkers are needed to determine whether anticoagulation can be safely stopped in a subset of IBD

79 VTE off anticoagulation, risk of bleeding on anticoagulation, case fatality or all-cause mortality, a

80 n, 1 stroke (718 patient-years) with 81% off anticoagulation, catheter ablation reinterventions in 13

81 Patients were characterized by baseline oral anticoagulation, CHADS2 and CHA2DS2-VASc scores, AF diag

82 treatment with anticoagulants at the Leiden Anticoagulation Clinic in the Netherlands between 2003 a

83 We outline 3 key purposes that a reimagined anticoagulation clinic would serve: (1) to assist patien

84 ed for expanding the traditional role of the anticoagulation clinic.

85 edoxaban), many have questioned the need for anticoagulation clinic.

86 years or older who were new referrals to VA anticoagulation clinics (for warfarin therapy) between J

87 onwide data, including that from specialized anticoagulation clinics and primary health care centers.

88 We also describe how repurposing anticoagulation clinics as broader medication safety cli

89 Anticoagulation clinics were initially developed to prov

90 r a range of hemodynamic, hematological, and anticoagulation conditions could assist physicians to pe

91 ney injury and treated with regional citrate anticoagulation-continuous veno-venous hemodialysis duri

92 Of these, only HAS-BLED considers quality of anticoagulation control amongst vitamin K antagonist (VK

93 such patients may do well with high-quality anticoagulation control.

94 Anticoagulation, corticosteroids, intravenous immunoglob

95 f ischemic stroke associated with parenteral anticoagulation did not differ significantly between pat

96 1.1%/year), whereas 13 with apical clots and anticoagulation did not incur embolic events.

97 mechanical catheter-directed thrombolysis to anticoagulation did not result in a lower risk of the po

98 is a major complication of regional citrate anticoagulation during continuous renal replacement ther

99 warfarin therapy should not receive bridging anticoagulation during periprocedural interruptions of t

100 hospital stroke and bleeding associated with anticoagulation during sepsis.

101 embolization for bivalirudin versus heparin anticoagulation during TAVR.

102 intraventricular hemorrhage, and reversal of anticoagulation during the acute phase.

103 Lifelong oral anticoagulation, either with warfarin or a non-vitamin K

104 ver, no direct evidence of benefit from oral anticoagulation exists in this population.

105 anticoagulation for AF as an instrument for anticoagulation exposure (RR for stroke, 1.08; 95% CI, 0

106 reflecting activation of procoagulation and anticoagulation, fibrinolysis, endothelial cell activati

107 inferior vena cava filter implantation plus anticoagulation (filter group; n = 200) or anticoagulati

108 V thrombosis and the value of empirical oral anticoagulation following BPV implantation.

109 All patients received anticoagulation for 12 months or until complete recanali

110 ing hospital utilization rates of parenteral anticoagulation for AF as an instrument for anticoagulat

111 tion, but risks and benefits associated with anticoagulation for AF during sepsis are unclear.

112 e done to evaluate the potential benefits of anticoagulation for all patients who have both and the p

113 Anticoagulation for at least 3 months or the duration of

114 ent, speech language pathology consultation, anticoagulation for atrial fibrillation, discharge on st

115 est prospective randomised clinical trial of anticoagulation for cardioversion of patients with non-v

116 Anticoagulation for mechanical heart valves during pregn

117 However, the role of anticoagulation for preventing dementia attributed to AF

118 e-related pulmonary hypertension is based on anticoagulation for those with thromboembolism; oxygen t

119 unacceptable health risk" during established anticoagulation for VTE.

120 ternational normalized ratio <1.7) or not on anticoagulation from 1289 registry hospitals between Oct

121 ban group and 3.4% (69/2010) in the standard anticoagulation group (propensity score-adjusted HR 0.51

122 ban group and 2.3% (47/2010) in the standard anticoagulation group (propensity score-adjusted HR 0.91

123 atelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1).

124 group vs 805 [37.5%] of 2149 in the standard anticoagulation group).

125 ban group and 2.1% (43/2010) in the standard anticoagulation group, with a propensity score-adjusted

126 ulmonary embolism than those in the standard anticoagulation group.

127 However, oral anticoagulation has been associated with an increased ri

128 ts, and its cost effectiveness compared with anticoagulation has not been evaluated using all availab

129 w any differences with regard to hemostasis, anticoagulation, hemolysis, and inflammatory parameters

130 Therefore hemostasis, anticoagulation, hemolysis, and inflammatory parameters

131 ant associations of dIVH were prior warfarin anticoagulation, high (>/=15) baseline National Institut

132 ivariable analyses adjusted for alcohol use, anticoagulation, hypercholesterolemia, education, and me

133 ervation, etc), and postoperatively (refined anticoagulation, improved wound dressings, etc).

134 ysicians attempted to administer therapeutic anticoagulation in 243 patients (63.3%), leaving 141 con

135 citrate accumulation during regional citrate anticoagulation in a well-selected cohort of patients is

136 Further research should be made on whether anticoagulation in antibody-positive patients could amel

137 (VKAs) is closely related to the quality of anticoagulation in atrial fibrillation (AF) patients, re

138 The benefit of oral anticoagulation in atrial fibrillation is based on a bal

139 e AP and inhibition of activated PC-mediated anticoagulation in GMVECs by the inflammatory cytokine T

140 Inhibiting anticoagulation in mice by using small interfering RNA (

141 nsus guidelines generally suggest continuing anticoagulation in patients with active cancer or receiv

142 l intervention, aimed to improve use of oral anticoagulation in patients with atrial fibrillation and

143 The optimal duration of anticoagulation in patients with cancer-associated venou

144 efforts will establish when to initiate oral anticoagulation in patients with device-detected atrial

145 on is warranted when considering therapeutic anticoagulation in patients with high-grade gliomas give

146 clinicians navigate the intricate process of anticoagulation in pregnancy.

147 oled the existing evidence to assess whether anticoagulation in the setting of a new bioprosthesis wa

148 a-analysis of previous studies suggests that anticoagulation in the setting of an aortic bioprosthesi

149 n with rivaroxaban for Long-term and Initial Anticoagulation in venous thromboembolism (XALIA) was a

150 ated for determining the optimal duration of anticoagulation in VTE patients, for diagnosing and moni

151 risk for stroke and would be candidates for anticoagulation in whom there is concern about the risk/

152 nsion, type 2 diabetes, previous stroke, and anticoagulation, incident AF patients with vs without an

153 n; 12751 (13.5%) had subtherapeutic warfarin anticoagulation (INR <2) at the time of stroke, 37674 (3

154 lar assist devices (CF-LVADs), stratified by anticoagulation intensity.

155 Periprocedural management of anticoagulation is a common clinical conundrum that invo

156 Therapeutic anticoagulation is associated with a reduction of these

157 ria, the role of devices in patients in whom anticoagulation is contraindicated, and the relative rol

158 brillation (AF) modifies the risk/benefit of anticoagulation is controversial.

159 In transplantation, systemic anticoagulation is difficult due to bleeding.

160 Oral anticoagulation is highly effective in reducing recurren

161 Life-long anticoagulation is indicated after the first episode of

162 Our data suggest that therapeutic anticoagulation is not necessary for grade 1 and 2 arter

163 Anticoagulation is often avoided in patients with atrial

164 Whereas long-term anticoagulation is required to prevent thromboembolism a

165 it has been established that the efficacy of anticoagulation is superior to that of antiplatelet agen

166 Oral anticoagulation is underused in patients with atrial fib

167 Future investigations should evaluate anticoagulation management as well as brain/extracorpore

168 Short-term anticoagulation may be appropriate for all patients afte

169 arlier identification of AF with appropriate anticoagulation may decrease stroke morbidity and mortal

170 evere strokes than did those who were not on anticoagulation (median National Institutes of Health St

171 eveloped that employs standard practices for anticoagulation monitoring.

172 , and management strategies that incorporate anticoagulation must weigh a treatment that carries a ri

173 ient groups included antiplatelet (n = 181), anticoagulation (n = 91), and no therapy (n = 6).

174 Women requiring anticoagulation need careful attention throughout pregna

175 delines emphasize the important role of oral anticoagulation (OAC) for effective stroke prevention in

176 Natick, MA) is an alternative option to oral anticoagulation (OAC) for stroke prevention in atrial fi

177 Oral anticoagulation (OAC) independent of CHA2DS2-VASc score

178 Oral anticoagulation (OAC) is the mainstay of thromboembolism

179 mporal trends of initiation patterns of oral anticoagulation (OAC) treatment according to age.

180 c risk stratification and initiation of oral anticoagulation (OAC) was recommended in the 2014 Americ

181 Patients receiving oral anticoagulation (OAC) who undergo drug-eluting stent (DE

182 Oral anticoagulation (OAC) with warfarin is underused for atr

183 Oral anticoagulation (OAC), rather than aspirin, is recommend

184 efficiency of heparin-free regional citrate anticoagulation of the dialysis circuit using a calcium-

185 key challenges to implementing a reimagined anticoagulation or medication safety clinic structure.

186 s, and elevated transcatheter gradients with anticoagulation or surgical or pathological confirmation

187 al ischemic stroke rate where the benefit of anticoagulation outweighs the bleeding risk (net clinica

188 ; p = 0.025) and were more likely to receive anticoagulation (p < 0.001).

189 t difference according to the indication for anticoagulation (P for heterogeneity = .49) or the novel

190 t, patients with previous experience of oral anticoagulation, patients who did not have a prescriptio

191 her anticoagulation alone (control group) or anticoagulation plus pharmacomechanical thrombolysis (ca

192 ge; and 6) outline the process of restarting anticoagulation post-procedure.

193 Demographics, anticoagulation practices, severity of illness, circuitr

194 cute ischemic stroke, inadequate therapeutic anticoagulation preceding the stroke was prevalent.

195 Not having oral anticoagulation prescribed at baseline and having AF fir

196 This resulted in oral anticoagulation prescription in 94.7% of ICM patients wi

197 In mediation analysis, oral anticoagulation prescription within 90 days of diagnosis

198 th a chronic calf DVT, a contraindication to anticoagulation, prior venous thromboembolism within 180

199 Embolic events were less common with anticoagulation prophylaxis (4/233, 2%) than without (9/

200 veloping E-HAT, and intense surveillance and anticoagulation prophylaxis may avoid this serious compl

201 25% (brain imaging; carotid imaging) to 99% (anticoagulation quality).

202 ients (1.6%); PE, in 6 controls (4.3%) and 4 anticoagulation recipients (1.6%).

203 imal DVT occurred in 7 controls (5.0%) and 4 anticoagulation recipients (1.6%); PE, in 6 controls (4.

204 Oral anticoagulation reduces the risk of mortality in atrial

205 Anticoagulation reduces thromboembolic complications; th

206 effective and safe alternatives to standard anticoagulation regimens.

207 not (185 of 13505 [1.4%]) receive parenteral anticoagulation (relative risk [RR], 0.94; 95% CI, 0.77-

208 y estimates on the risk of recurrent VTE off anticoagulation, risk of bleeding on anticoagulation, ca

209 Perhaps anticoagulation should be the preferred preventive strat

210 nt comorbidities, general health status, and anticoagulation status.

211 e independent of the TEE-guided strategy and anticoagulation status.

212 to investigate whether parenteral procedural anticoagulation strategies affect cerebral embolization.

213 The comparative efficacy of various anticoagulation strategies has not been clearly establis

214 that ordinarily necessitate consideration of anticoagulation, such as arterial and venous thrombotic

215 We collected data on type and dosage of anticoagulation; suspected or confirmed bleeding events,

216 REG1 is a novel anticoagulation system consisting of pegnivacogin, an RN

217 In comparison with those not on anticoagulation, the adjusted odds ratio for symptomatic

218 s thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was signi

219 veness of rivaroxaban compared with standard anticoagulation therapy (initial treatment with unfracti

220 nferior and probably safer than conventional anticoagulation therapy (low-molecular-weight heparin fo

221 nting a CIED to detect AF or initiating oral anticoagulation therapy among those in whom AF is detect

222 udy patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding

223 gnificant valvular disease, decisions around anticoagulation therapy are first based on the presence

224 The absence of anticoagulation therapy at hospital discharge (p = 0.002

225 Clinicians should consider alternative anticoagulation therapy for patients with suboptimal out

226 Oral anticoagulation therapy for stroke prevention has simila

227 losure has emerged as a valid alternative to anticoagulation therapy for the prevention of stroke/sys

228 a safe and effective alternative to standard anticoagulation therapy in a broad range of patients.

229 sk of TEC in this population and the role of anticoagulation therapy in TEC prevention.

230 efficacy, safety, and economic value of oral anticoagulation therapy in this population.

231 Chronic oral anticoagulation therapy is the standard therapy for prev

232 it is better to use full- or lower-intensity anticoagulation therapy or aspirin.

233 ents who use extracorporeal devices, receive anticoagulation therapy or experience coagulopathies.

234 e pivotal Randomized Evaluation of Long-Term Anticoagulation Therapy trial.

235 age of patients subsequently prescribed oral anticoagulation therapy was also determined.

236 pisodes lasting 24 hours or longer, and oral anticoagulation therapy was prescribed for 72 patients (

237 LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy).

238 The lack of anticoagulation therapy, a valve-in-valve procedure, a g

239 or prasugrel/ticagrelor and fondaparinux for anticoagulation therapy, and a preference for radial art

240 o-femoral junction, indication for full-dose anticoagulation therapy, and substantial hepatic or rena

241 After 2 years of anticoagulation therapy, health care costs (excluding th

242 to thrombosis diagnosed based on response to anticoagulation therapy, imaging modality or histopathol

243 ity of patients with AF were prescribed oral anticoagulation therapy.

244 in 1 and mild residual narrowing in 2 after anticoagulation therapy.

245 patients with atrial fibrillation receiving anticoagulation therapy.

246 pillars of rate control, rhythm control, and anticoagulation therapy.

247 e, supporting a low threshold for initiating anticoagulation therapy.

248 ially mediated by early prescription of oral anticoagulation therapy.

249 for enrolment into clinical trials comparing anticoagulation to antiplatelet therapy in secondary str

250 s are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of h

251 Oral anticoagulation treatment (OAT) resumption is a therapeu

252 ate the proportion of patients discontinuing anticoagulation treatment after PVI in association with

253 osed AF earlier, leading to appropriate oral anticoagulation treatment and a reduction in stroke/TIA

254 ein thrombosis, and an indication to receive anticoagulation treatment for at least 3 months.

255 and should be useful as decision support on anticoagulation treatment in patients with atrial fibril

256 ly, patients with other indications for oral anticoagulation treatment, patients with previous experi

257 VCF use only in patients who cannot receive anticoagulation treatment.

258 ients with and without guideline-recommended anticoagulation treatment.

259 rrent VTE in patients with cancer who are on anticoagulation treatment.

260 80 697 patients with no contraindication to anticoagulation, VCF use (n=7762, 9.6%) did not signific

261 A mean duration of anticoagulation was 10 months (range, 4-20).

262 Anticoagulation was also associated with lower risk of d

263 Moreover, anticoagulation was also not shown to improve outcomes a

264 in was analyzed as a time-varying covariate, anticoagulation was associated with a >13-fold increased

265 Therapeutic anticoagulation was associated with a decreased risk for

266 Therapeutic anticoagulation was associated with lower odds of modera

267 Anticoagulation was associated with lower TEC rate and l

268 Continuous renal replacement therapy without anticoagulation was more likely to cause clotting compar

269 g patients with AF during sepsis, parenteral anticoagulation was not associated with reduced risk of

270 Anticoagulation was protective against TEC and resulted

271 Oral anticoagulation was stopped before the procedure.

272 to AF (thromboembolism without prophylactic anticoagulation) was 0.1% per year (n=2 patients).

273 AuriculA, a quality register for AF and oral anticoagulation, was conducted.

274 Patients on anticoagulation were excluded.

275 Multimodality Imaging and Its Treatment with Anticoagulation) were included in this analysis.

276 d clopidogrel and without indication to oral anticoagulation-were pooled at a single-patient level fr

277 th an unprovoked DVT and one with DVT during anticoagulation, will be presented.

278 ion (PCI) with placement of stents, standard anticoagulation with a vitamin K antagonist plus dual an

279 n groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was perf

280 the comparative effectiveness of procedural anticoagulation with bivalirudin compared with unfractio

281 that cerebral embolization may be reduced by anticoagulation with bivalirudin during TAVR.

282 eripheral vascular interventions, procedural anticoagulation with bivalirudin may result in more favo

283 dy was to examine the outcomes of procedural anticoagulation with bivalirudin versus heparin +/- GPI

284 Dialysis anticoagulation with calcium-free citrate-containing dia

285 hout VHD in the ENGAGE AF-TIMI 48 (Effective Anticoagulation with factor Xa Next Generation in Atrial

286 l) in the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial

287 warfarin in the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial

288 In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial

289 n patients with ischemic stroke who received anticoagulation with NOACs versus those on warfarin (int

290 y in women aged <60 years who were receiving anticoagulation with rivaroxaban or enoxaparin/VKA for c

291 The effectiveness and safety of anticoagulation with rivaroxaban plus either one or two

292 on; 3) provide direction on how to interrupt anticoagulation with specific guidance for vitamin K ant

293 with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the r

294 al studies or clinical trials) that assessed anticoagulation with warfarin in comparison with either

295 follow-up and resolved after increased oral anticoagulation with warfarin.

296 cribe the available treatment options beyond anticoagulation, with a focus on the interventional appr

297 t properties may predict recurrent DVT after anticoagulation withdrawal.

298 heparin-free easy-to-use alternative type of anticoagulation within the dialysis circuit.

299 eloped by the American College of Cardiology Anticoagulation Work Group.

300 We hypothesized that forgoing bridging anticoagulation would be noninferior to bridging with lo